COMPASS Pathways’ (CMPS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of COMPASS Pathways (NASDAQ:CMPS) in a research note published on Monday morning,Benzinga reports. They currently have a $45.00 price objective on the stock.

Several other research analysts have also recently issued reports on the stock. Stifel Nicolaus started coverage on shares of COMPASS Pathways in a report on Thursday, February 27th. They issued a “buy” rating and a $11.00 target price on the stock. Canaccord Genuity Group cut their price objective on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, February 28th. Royal Bank of Canada reissued an “outperform” rating and set a $18.00 price objective on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a report on Friday, March 28th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $20.20.

COMPASS Pathways Stock Performance

Shares of CMPS stock opened at $3.86 on Monday. COMPASS Pathways has a 12 month low of $2.49 and a 12 month high of $8.54. The firm’s 50 day moving average is $3.34 and its 200 day moving average is $3.99. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $358.40 million, a P/E ratio of -1.75 and a beta of 2.27.

COMPASS Pathways (NASDAQ:CMPS) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.03. On average, sell-side analysts anticipate that COMPASS Pathways will post -2.33 earnings per share for the current year.

Institutional Investors Weigh In On COMPASS Pathways

Large investors have recently bought and sold shares of the company. Cerity Partners LLC purchased a new stake in COMPASS Pathways during the 1st quarter valued at about $29,000. GAMMA Investing LLC grew its position in shares of COMPASS Pathways by 93.6% in the first quarter. GAMMA Investing LLC now owns 10,349 shares of the company’s stock valued at $30,000 after purchasing an additional 5,003 shares in the last quarter. Ethos Financial Group LLC acquired a new stake in shares of COMPASS Pathways in the first quarter valued at approximately $35,000. China Universal Asset Management Co. Ltd. purchased a new position in COMPASS Pathways during the fourth quarter worth approximately $41,000. Finally, Flagship Harbor Advisors LLC boosted its stake in COMPASS Pathways by 27.7% during the first quarter. Flagship Harbor Advisors LLC now owns 14,446 shares of the company’s stock worth $41,000 after buying an additional 3,134 shares during the last quarter. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.